Infusion Options, Inc. is recalling 820 units of Oxytocin 60 units/1000 mL and dozens of other compounded intravenous (IV) solutions, including cancer treatments and electrolyte replacements. These medications were recalled because they may not be sterile, which could lead to life-threatening infections if administered. The affected products were distributed exclusively in New York and were produced under conditions that cannot guarantee the safety of the injectable medication.
The lack of sterility assurance means these medications could contain bacteria or fungi. Injecting a non-sterile product directly into the bloodstream or under the skin can cause severe, life-threatening infections such as sepsis or meningitis.
Healthcare guidance and product return
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.